Vericel Corporation

As of June 30, 2026, Vericel Corporation carries a market capitalization of 1.99B, placing it among publicly traded companies globally. Its enterprise value stands at 1.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vericel Corporation's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Vericel Corporation has 51.17M shares outstanding.

As of June 30, 2026, Vericel Corporation trades at a trailing price-to-earnings ratio of 92.85. The price-to-sales ratio is 7.34, and the price-to-book ratio stands at 6.13.

As of June 30, 2026, Vericel Corporation trades at an EV/EBITDA multiple of 70.57 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 120.56 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Vericel Corporation trades at an EV/FCF ratio of 31.27, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.92B versus a market cap of 1.99B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vericel Corporation maintains a current ratio of 5.04, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.04, indicating elevated leverage, while an interest coverage ratio of 48.68 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Vericel Corporation posted a return on equity (ROE) of 7.16, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.20 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.16, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.72, useful for judging operating efficiency across full business cycles. The company generates approximately 691,442.98 in revenue per employee across its workforce of 387.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.43 indicates how many times Vericel Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Vericel Corporation's stock has gained approximately 23.08% over the past 52 weeks. The 50-day moving average sits at 35.55, while the 200-day moving average is 33.38.

Over the twelve months ended June 30, 2026, Vericel Corporation generated 268.11M in revenue and converted that into 21.20M in net income, yielding earnings per share of 0.41. EBITDA reached 27.27M, while operating income came in at 15.96M.

As of June 30, 2026, Vericel Corporation holds 142.20M in cash and equivalents against 81.10M in total debt, resulting in a net debt position of -109.73M. Total book value stands at 323.90M, with working capital of 185.74M providing operational flexibility.

Vericel Corporation produced 60.98M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Vericel Corporation posted a gross margin of 74.56, reflecting its pricing power and cost economics. The operating margin of 5.95 and net profit margin of 7.91 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.04, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.09, meaning Vericel Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Vericel Corporation's most recent stock split took place on October 16, 2013 with a 20:1 split ratio.

As of June 30, 2026, Vericel Corporation has an Altman Z-Score of 10.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.